⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JUNS News
Jupiter Neurosciences, Inc. Common Stock
Form 8-K
sec.gov
JUNS
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
globenewswire.com
JUNS
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
accessnewswire.com
JUNS
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
globenewswire.com
JUNS
Form 8-K
sec.gov
JUNS
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
globenewswire.com
JUNS
Form 8-K
sec.gov
JUNS
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
globenewswire.com
JUNS
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
globenewswire.com
JUNS
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit Ready to Announce with Confidence?
newsfilecorp.com
JUNS